MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
VEGF bispecifics enter the conjugate era
JSKN027 will become the first ADC with this mechanism to enter human trials.
Karyopharm investors fasten their seatbelts
A binary Xpovio catalyst is set for March.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
